Skip Navigation

Lotus Reported Unaudited May Revenues of NT$1,553 million

07 June 2024

Taipei, Taiwan, June 7, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, has disclosed its unaudited consolidated revenue for May 2024, reaching NT$1,553 million, marking a 17.5% year-over-year increase, primarily driven by increased shipments of Lenalidomide to the US and strong revenue growth in its Asian markets.


The company's Asian revenue saw a 6.6% year-over-year increase in May. Specifically, Taiwan's revenue grew by 6.8% compared to the same month last year, while other Asian markets experienced a substantial 95% year-on-year increase, largely due to the replenishment of vinorelbine soft gel to Vietnam. Export revenues also grew by 32% this month compared to the previous year, with lenalidomide shipments to the US being the main contributor.


On June 6th, Lotus announced the acquisition of TEVA Pharma Thailand, marking its inaugural M&A deal in Southeast Asia and positioning Thailand as a potential hub for regional expansion. This acquisition will not only expand Lotus's existing oncology and women's health product lines but also provide access to Teva’s ophthalmic and respiratory portfolios, allowing Lotus to enter pharmacy channels in Thailand. Following the expected closing of the acquisition in Q3, Lotus expands its Thailand team to nearly 100 members, positioning itself as a key player in the Thailand pharmaceutical market.


About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

Media Inquiries:

Yu-ying Yang, Associate Director, Cooperate communication.

+886 2 2700 5908